Compare · FWP vs NVO
FWP vs NVO
Side-by-side comparison of Forward Pharma A/S (FWP) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FWP and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.82B, about 3383.7x FWP ($54.3M).
- NVO has hit the wire 5 times in the past 4 weeks while FWP has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 0 for FWP).
- Company
- Forward Pharma A/S
- Novo Nordisk A/S
- Price
- $1.95+0.00%
- $41.18+6.93%
- Market cap
- $54.3M
- $183.82B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2014
- News (4w)
- 0
- 5
- Recent ratings
- 0
- 25
Forward Pharma A/S
Forward Pharma A/S does not have significant operations. Previously, it operated as a biopharmaceutical company that focused on developing proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. The company was incorporated in 2005 and is headquartered in Copenhagen, Denmark.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest FWP
- SEC Form SC 13G/A filed by Forward Pharma A/S (Amendment)
- SEC Form EFFECT filed by Forward Pharma A/S
- SEC Form POS AM filed by Forward Pharma A/S
- SEC Form S-8 POS filed by Forward Pharma A/S
- SEC Form S-8 POS filed by Forward Pharma A/S
- SEC Form 15-12G filed by Forward Pharma A/S
- SEC Form 6-K filed by Forward Pharma A/S
- SEC Form 25-NSE filed by Forward Pharma A/S
- SEC Form SC 13G filed by Forward Pharma A/S
- SEC Form 6-K filed by Forward Pharma A/S
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S